← Back to Screener
Quince Therapeutics, Inc. Common Stock (QNCX)
Price$1.03
Momentum ScoreF
Favorite Metrics
Price vs S&P 500 (26W)-109.38%
Price vs S&P 500 (4W)-19.58%
VGM Score19.13
Market Capitalization$17.12M
All Metrics
Book Value / Share (Quarterly)$1.14
P/TBV (Annual)2.10x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.88
Price vs S&P 500 (YTD)-108.25%
EPS (TTM)$-9.11
10-Day Avg Trading Volume1.11M
EPS Excl Extra (TTM)$-9.11
EPS (Annual)$-16.76
ROI (Annual)-127.80%
Cash / Share (Quarterly)$1.32
ROA (Last FY)-89.80%
EBITD / Share (TTM)$-9.29
ROE (5Y Avg)-79.44%
Cash Flow / Share (Annual)$-7.50
P/B Ratio1.09x
P/B Ratio (Quarterly)0.36x
Net Income / Employee (Annual)$-2,210,000
Net Interest Coverage (TTM)-33.67x
ROA (TTM)-38.06%
EPS Incl Extra (Annual)$-16.76
Current Ratio (Annual)0.53x
Quick Ratio (Quarterly)2.82x
3-Month Avg Trading Volume7.76M
52-Week Price Return-90.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.14
52-Week High$45.50
EPS Excl Extra (Annual)$-16.76
CapEx CAGR (5Y)47.75%
26-Week Price Return-95.80%
Quick Ratio (Annual)0.50x
13-Week Price Return6.06%
Total Debt / Equity (Annual)0.48x
Current Ratio (Quarterly)2.92x
Enterprise Value$-1.05M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.19
3-Month Return Std Dev215.16%
Net Income / Employee (TTM)$-869,400
ROE (Last FY)-188.51%
EPS Basic Excl Extra (Annual)$-16.76
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-9.11
ROI (TTM)30.59%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$4.98
Price vs S&P 500 (52W)-118.25%
Year-to-Date Return-96.87%
5-Day Price Return-8.70%
EPS Normalized (Annual)$-16.76
ROA (5Y Avg)-55.08%
Month-to-Date Return-8.70%
Cash Flow / Share (TTM)$-0.78
EBITD / Share (Annual)$-11.56
LT Debt / Equity (Annual)0.48x
ROI (5Y Avg)-66.28%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-9.11
P/TBV (Quarterly)0.36x
P/B Ratio (Annual)2.73x
Book Value / Share (Annual)$6.85
Price vs S&P 500 (13W)-4.60%
Beta1.35x
Revenue / Share (TTM)$0.00
ROE (TTM)67.67%
52-Week Low$0.79
mGradeF
vgmGradeF
Show chart for
Earnings Surprise History
Q4 25-7.10est. -1.93
Q1 262.88est. -2.61
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.64
2.33
2.33
2.33
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
QNCXQuince Therapeutics, Inc. Common Stock | — | — | F | $1.03 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
Quince Therapeutics is a preclinical-stage biopharmaceutical company developing a bone-targeting platform designed to deliver therapeutics directly to fracture and disease sites while reducing systemic side effects. The platform can accommodate small molecules, peptides, and large molecules. The company's pipeline includes programs in Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, with expansion potential into additional indications.